MRNA Moderna Inc
Company Analysis
Latest News
🟢 Moderna is trading 4.72% up today after Phase 3 trial met recurrence-free-survival endpoint
Moderna is trading 4.72% up at $190.70 after positive Phase 3 INTerpath-001 results for intismeran autogene with Merck’s Keytruda. - The trial met its...
🟢 Moderna is trading 4.48% up today after Phase 3 trial met survival endpoints
Moderna is trading 4.48% up now at $190.74 as investors respond to positive Phase 3 melanoma results for intismeran autogene with Merck’s Keytruda. -...
🟢 Moderna is trading 5% up today after positive Phase 3 melanoma results
Moderna is trading 5% up at $181.61 after Moderna and Merck announced positive Phase 3 melanoma results. - The rally extends Moderna’s 12.27% gain on...
Moderna Lands the Biggest Stage in Cancer Medicine — But Can a Conference Slot Justify a $7 Billion Single-Day Gain?
Shares of Moderna surged 10.8% to $170.63 Monday after the company announced its personalized mRNA melanoma vaccine data secured a coveted Presidential...
🟢 Moderna is trading 10.77% up today after melanoma-vaccine data secured Presidential Symposium placement
Moderna is trading $170.63 (+10.77%) after announcing on September 21, 2026, that Phase 3 melanoma-vaccine data for intismeran autogene will receive a...
🟢 Moderna is trading 5% up today as U.S. equities open higher
Moderna is trading 5% up now at $161.72, as U.S. equities open higher. - The S&P 500 is up 0.65%, while the Nasdaq Composite is up 0.90%. - The move appears...
Moderna loses key mRNA patent, reversing European legal victories
The European Patent Office (EPO) Boards of Appeal revoked Moderna’s patent EP 3 590 949. This patent is central to Moderna's ongoing legal disputes with Pfizer...
🟢 Moderna is trading 10% up today as markets recover after September 16 rate hike
Moderna is trading at $160.30, up +10.08%, as U.S. markets recover after the Federal Reserve’s September 16 rate hike, which removed immediate policy...
🟢 Moderna is trading 6.74% up today as markets recover after September 16 Fed decision
Moderna is trading at $158.65, with a +6.74% gain during the September 17, 2026 session as broader U.S. markets recover after the Federal Reserve’s September...
🟢 Moderna is trading 4.3% up in pre-market after Fed’s September 16 rate decision
Moderna is trading 4.32% up at $151.91 after a firm broader-market recovery following the Federal Reserve’s September 16 rate decision. - Major U.S. indices...
🟢 Moderna is trading 5.7% up today after in-line August inflation data
Moderna is trading at $144.39 (+5.69%) as broad U.S. markets rally after August inflation matched expectations. - Broad market rally followed 3.4% August CPI,...
Moderna wins UK approval for Spikevax, securing 2026/27 NHS supply deal
The UK Medicines and Healthcare products Regulatory Agency (MHRA) authorized Moderna’s updated Spikevax vaccine. This version targets the circulating...
🔴 Moderna is trading 4.75% down today after Rothschild Redburn downgraded shares to Sell
Moderna is trading 4.75% down at $141.79 after Rothschild & Co. Redburn downgraded the shares to Sell from Neutral and raised its price target to $81 from $40,...
🟢 Moderna is trading 4.12% up in pre-market with no fresh company-specific catalyst identified
Moderna is trading 4.12% up now at $155.00 in pre-market, with no fresh company-specific announcement clearly explaining the move. - It is based on the...
🔴 Moderna is trading 4.6% down today after Rothschild & Co. Redburn downgraded to Sell
Moderna is trading 4.6% down now at $143.88 after Rothschild & Co. Redburn downgraded the stock from Neutral to Sell, citing valuation concerns following its...
Moderna Downgraded to 'Sell' by Rothschild & Co. on Valuation Concerns
Rothschild & Co. Redburn downgraded Moderna (NASDAQ:MRNA) from "neutral" to "sell," citing valuation concerns following a significant stock price increase....
🔴 Moderna is trading 4.5% down today after possible profit-taking following melanoma-vaccine surge
Moderna is trading at $147.38 (-4.46%), as investors may be taking profits after the melanoma-vaccine surge. - It is reversing part of its 9.93% gain from...
Moderna Completes $3.0 Billion Offering of 0.00% Convertible Senior Notes Due 2032
Moderna has completed its previously announced private offering of $3.0 billion in aggregate principal amount of 0.00% Convertible Senior Notes due 2032. This...
🟢 Moderna is trading 10% up today after GSK advances mRNA flu vaccine
Moderna is trading at $154.38, up +10.01%, after GSK’s decision to advance an mRNA flu vaccine into Phase III was interpreted as validation of Moderna’s...
Moderna Faces GSK in Key mRNA Patent Hearing in The Hague
Moderna faces a patent infringement hearing today, September 1. The hearing is at the Unified Patent Court's local division in The Hague. GlaxoSmithKline...